Payor preferences, clinic workload bring at-home testing to the forefront
Across fertility centers, clinical workload has reached a breaking point. Nurses, physicians, and embryologists are operating under compounding pressures — rising cycle volumes, complex care pathways, and increasingly demanding patient expectations. The daily reality for many teams involves balancing time-sensitive care with mounting administrative burden, often without sufficient operational support.
Fertility nurses are experiencing profound levels of exhaustion, often describing burnout as “a state of physical, emotional, and mental exhaustion caused by prolonged stress, leading to fatigue, loss of motivation, and a sense of detachment from work”. Many report that the emotional toll “leaks into your personal life”, making it difficult to recover between shifts and regroup for the next day’s patient load.
Others describe seasons of burnout as feeling like “depression, emotional drainage and not having anything left to give,” a level of depletion that affects both performance and confidence. One nurse explained that the most painful part is the sense that “you can’t show up as the nurse you know you are” when stress becomes overwhelming.
These pressures are felt not just on the clinic side, but in the IVF lab. Embryologists report spending large portions of their day on QC verification, troubleshooting consumables, and confirming equipment performance before procedures even begin. Lab director Dr. Michael Baker, PhD, HCLD(ABB) explained that his team is “hard-pressed for time already,” and that the additional internal testing required because of supplier variability has become “busy work” that takes attention away from embryo care.
His colleague, Dr. Robert Mendola, PhD, HCLD TS(ABB), shared similar experiences, recounting products that “passed manufacturer MEA tests but didn’t pass our end-user bioassay,” forcing the lab to create additional layers of QA. These pressures echo findings where physicians describe balancing rising patient demand with operational systems that have not kept pace.
The combination of rising workload and higher QC demands has positioned validated, at-home diagnostics as a strategic asset that can reduce internal burden while maintaining — and in some cases improving — diagnostic reliability.
Clinics Turn To Mail-In Testing To Reduce Workload
To reduce workload and administrative burden, clinics turned to at-home testing in greater numbers than ever before last year, including mail-in semen analysis.
Clinics report that having semen analysis completed before the initial consultation meaningfully reduces the number of appointments required to move from intake to treatment planning — a crucial advantage when clinical teams are already overstretched.
At-home testing is also transforming follow-up care. Historically, only 30–40% of vasectomy patients completed post-vasectomy semen analysis due to logistical barriers. Fellow Health’s New York State CLEP approval validates its mail-in PVSA under the country’s most stringent laboratory framework. Fellow’s Chief Medical Officer Dr. James F. Smith described this approval as “a validation of our commitment to scientific excellence.”
Today, more than 2,500 clinics, including 12 of the top 15 U.S. hospitals, rely on Fellow Health’s testing infrastructure. Its CLIA-certified lab processes 400+ samples daily, signaling the scalability needed to support rising diagnostic demand.
Fertility Benefits Managers Rely On At-Home Testing
Demand for at-home testing is rising sharply. Platforms like Maven are already seeing testing volumes triple compared to their early projections — driven largely by patient curiosity and earlier engagement in male-factor evaluation.
Fellow Health’s integration into the Progyny network offers eligible members access to CLIA-certified mail-in semen analysis as a covered benefit. Progyny’s Chief Medical Officer Dr. Janet Choi emphasized that with nearly 50% of fertility cases involving male factor infertility, early testing is essential for more productive, informed first visits.
Investors Pour $24M Into Fellow As Clinical Standards Rise
New York’s CLEP program — known for requirements that meet or exceed federal CLIA standards — is a new benchmark for diagnostic credibility. CLEP approval of Fellow’s PVSA sets a new expectation for the entire category: home-collected samples must meet the same standards as in-clinic analysis. This signals a shift away from early consumer-grade versions of at-home testing toward higher clinical standards..
Investor confidence reinforced this trajectory. There is a growing interest in the male reproductive diagnostics category. The Series B brings Fellow’s total raised to $48 million, funding expanded test offerings and deeper integration into employer-sponsored benefits.
With thousands of repeat tests processed through centralized labs, the category is developing one of the largest longitudinal male reproductive datasets — offering potential future insights into lifestyle, environmental factors, and reproductive health trajectories.
As clinical teams confront mounting workload and QC pressures, validated mail-in testing models provide a path to earlier diagnostic clarity and reduced internal burden. With expanding payor integration, at-home diagnostics are becoming a core component of fertility care in the late 2020s.
You Can Stop Being Left Out Now, Y’Know
Next Big Exposure Before PCRS. Why miss out when you get so much for so little? 🤪
If your organization belongs to this category but wasn’t included in this “State of” report, then your competitors are dominating the attention of your customers: REIs, fertility network executives, embryologists, and others.
These same competitors will get more coverage in a report or podcast episode, about your category
To start the year
Before PCRS
Before ESHRE
Before ASRM
Why let them get all the attention?
If you don’t want to miss out before PCRS, you have to join the IVF Heroes Universe as a sponsor now, before the next deadline.
You read it. Your employees read it. Your customers read it. Why miss out when you get so much for so little? 🤪